Breaking News Instant updates and real-time market news.

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

, CELG

Celgene

$104.82

-1.18 (-1.11%)

17:41
01/16/18
01/16
17:41
01/16/18
17:41

On The Fly: After Hours Movers

HIGHER: Juno Therapeutics (JUNO), up 41.5% after the Wall Street Journal reported that it is in talks to be acquired by Celgene (CELG)... Newater Technology (NEWA), up 26.1% after the company and NW Blockchain announced a strategic partnership... Verso (VRS), up 10.3% after it expanded strategic alternatives to include a potential sale or merger... Exelixis (EXEL), up 3.5% after it and Ipsen (IPSEY) said that cabozantinib provided a statistically significant and clinically meangingful improvement versus placebo in overall survival in a pivotal phase 3 trial. DOWN AFTER EARNINGS: Renasant (RNST), down 4.2%... Interactive Brokers (IBKR), down 2.9%... CSX (CSX), down 1.3%. ALSO LOWER: A10 Networks (ATEN), down 22.7% after reporting preliminary fourth quarter results... HTG Molecular (HTGM), down 18.6% after it filed to sell $10M shares of common stock... Aerohive Networks (HIVE), down 15.8% after announcing preliminary Q4 results... Obalon Therapeutics (OBLN), down 11.7% after it filed to sell $35M in common stock... Intrexon (XON), down 7% after it filed to sell common stock... Boot Barn (BOOT), down 4.5% after it filed to sell 5.5M shares of common stock for holders... Ford (F), down 1.9% after it announced increased investment in electric vehicles and provided guidance for fiscal 2017 and 2018... Celgene, down 1.7% after the Wall Street Journal reported that it was in talks to acquire Juno Therapeutics.

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

NEWA

Newater Technology

$15.80

2.8 (21.54%)

VRS

Verso

$17.00

0.06 (0.35%)

EXEL

Exelixis

$29.65

-0.73 (-2.40%)

IPSEY

Ipsen

RNST

Renasant

$43.86

0.15 (0.34%)

IBKR

Interactive Brokers

$62.45

-0.65 (-1.03%)

CSX

CSX

$58.13

-1.12 (-1.89%)

ATEN

A10 Networks

$7.31

-0.27 (-3.56%)

HTGM

HTG Molecular

$3.50

-0.14 (-3.85%)

HIVE

Aerohive

$5.70

-0.19 (-3.23%)

OBLN

Obalon Therapeutics

$7.93

0.03 (0.38%)

XON

Intrexon

$13.77

-0.94 (-6.39%)

BOOT

Boot Barn

$19.10

-0.15 (-0.78%)

F

Ford

$13.10

-0.13 (-0.98%)

  • 16

    Jan

  • 16

    Jan

  • 16

    Jan

  • 17

    Jan

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 08

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 26

    Feb

  • 01

    Mar

  • 25

    Mar

  • 17

    Jan

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

JUNO Juno Therapeutics
$45.60

-3.15 (-6.46%)

11/03/17
RAJA
11/03/17
NO CHANGE
Target $61
RAJA
Outperform
Juno Therapeutics price target raised to $61 from $45 at Raymond James
Raymond James analyst Reni Benjamin raised Juno Therapeutics' price target to $61 from $45 and reiterated his Outperform rating following the Q3 report and update on all ongoing clinical programs. The analyst believes JCAR017 could potentially be a differentiated CAR T product and compete effectively with Yescarta and Kymriah. Further, with key readouts from multiple programs anticipated at upcoming medical conferences, the steady progress of the portfolio of products, including the BCMA CAR-T franchise as well as 5 products targeting solid tumors with data expected in 2018, and a strong cash position, Benjamin continues to recommend shares.
12/12/17
WELS
12/12/17
DOWNGRADE
Target $54
WELS
Market Perform
Juno Therapeutics downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough downgraded Juno Therapeutics (JUNO) to Market Perform and cut his price target for the shares to $54 from $66. While data for JCAR017 continue to support a potential best-in-class profile in aggressive lymphoma, the current valuation already reflects dominant market positioning over Gilead's (GILD) Yescarta, Birchenough tells investors in a research note. The analyst also sees "some risk" to waning efficacy at six months for JCAR017.
01/05/18
NEED
01/05/18
INITIATION
Target $65
NEED
Buy
Juno Therapeutics initiated with a Buy at Needham
Needham analyst Chad Messer initiated Juno Therapeutics (JUNO) with a Buy rating and a price target of $65. Messer says that while Novartis (NVS) and Gilead (GILD) have reached the CAR-T technology market ahead of Juno, the latter is "developing safer and potentially better products", positioning itself with "best-in-class technology". The analyst believes that the selloff in the stock price since the December ASH conference creates an attractive near-term entry point for investors.
12/12/17
12/12/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Juno Therapeutics (JUNO) downgraded to Market Perform from Outperform at Wells Fargo, with analyst Jim Birchenough saying that while data for JCAR017 continue to support a potential best-in-class profile in aggressive lymphoma, the current valuation already reflects dominant market positioning over Gilead's (GILD) Yescarta. 2. General Dynamics (GD) downgraded to Underweight from Neutral at JPMorgan, with analyst Seth Seifman saying Gulfstream questions are unlikely to be resolved in the near term. Demand for G500/600 is ok for now, but uncertainty about ultimate production levels and the pace of the learning curve mean the transition will remain a near term overhang, the analyst said. Seifman also downgraded Raytheon (RTN) to Neutral from Underweight. 3. Adobe (ADBE), Barracuda (CUDA), GoDaddy (GDDY), Fortinet (FTNT) and Check Point (CHKP) downgraded to Neutral from Overweight and CoStar Group (CSGP), Imperva (IMPV) and Monotype Imaging (TYPE) downgraded to Underweight from Overweight at JPMorgan by analyst Sterling Auty in conjunction with his 2018 annual outlook for Software Technology. The analyst does not expect the "exceptional performance" in Software during 2017 to repeat in 2018. 4. Spark Therapeutics (ONCE) downgraded to Neutral from Buy at UBS, with analyst Carter Gould seeing a "challenging setup" for the shares after the Phase 1/2 SPK-8011 data in hemophilia A fell short of expectations. The analyst removed SPK-8011, or $29 per share, and early-stage pipeline value, or $12 per share, from his model. He finds it difficult to be more constructive on Spark shares in the near-term. 5. Electronic Arts (EA) downgraded to Buy from Conviction Buy at Goldman Sachs by analyst Christopher Merwin to reflect fewer near-term catalysts around in-game monetization of non-sports titles. To see The Fly's full Street Research coverage, click here.
CELG Celgene
$104.82

-1.18 (-1.11%)

01/09/18
JEFF
01/09/18
NO CHANGE
Target $125
JEFF
Buy
Celgene likely 'too cheap and oversold,' says Jefferies
Jefferies analyst Michael Yee says that at 12 times earnings estimates, shares of Celgene are "probably too cheap and oversold." After meeting with management, Yee believes the company will do more deals following yesterday's acquisition of Impact. Further, he sees a potential share rebound on more pipeline readouts in 2018-2019. The analyst keeps a Buy rating on Celgene with a $125 price target.
01/09/18
BMOC
01/09/18
NO CHANGE
Target $147
BMOC
Outperform
Celgene 2018 outlook deliberately conservative, says BMO Capital
BMO Capital analyst M. Ian Somaiya says Celgene's 2018 guidance is "deliberately conservative", reflecting the management's decision to reduce the risk to near-term estimates amid investor focus on the company pipeline. Somaiya notes that investor focus is shifting to business development and the potential for more deals in the near-term as well as the data from the company's 12 phase III trials this year. The analyst keeps his Outperform rating and $147 price target on Celgene.
01/08/18
PIPR
01/08/18
NO CHANGE
Target $100
PIPR
Neutral
Celgene guidance 'a bit light' on sales, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond views Celgene's preliminary Q4 results as "solid' but says the company's initial 2018 outlook is "a bit light" on revenue. The better than expected earnings outlook looks to be driven by expense management and lower than modeled share count, Raymond tell investors in a research note. He keeps a Neutral rating on Celgene with a $100 price target.
01/08/18
ADAM
01/08/18
NO CHANGE
Target $140
ADAM
Buy
Celgene acquisition has 'interesting' upside potential, says Canaccord
After Celgene announced a deal to acquire Impact Biosciences for up to $7B, including an upfront payment of $1.1B, Canaccord analyst John Newman said the latter's JAK2 asset for myelofibrosis, fedratinib, showed an "interesting" 55% response rate in patients resistant or intolerant to Jakafi, which provides an immediately approvable FDA indication. This "carefully structured transaction" provides Celgene with substantial upside, assuming FDA approval, said Newman, who keeps a Buy rating and $140 price target on Celgene shares.
NEWA Newater Technology
$15.80

2.8 (21.54%)

VRS Verso
$17.00

0.06 (0.35%)

10/18/17
BWSF
10/18/17
UPGRADE
BWSF
Strong Buy
Verso upgraded to Strong Buy from Buy at BWS Financial
12/20/17
RILY
12/20/17
NO CHANGE
Target $20
RILY
Buy
Verso price target raised to $20 from $11.25 at B. Riley FBR
B. Riley FBR analyst Jeff Van Sinderen raised his price target for Verso to $20 saying positive industry environment trends have continued throughout Q4 and into 2018 contract negotiations. He notes the company is implementing various price increases as industry capacity has come off line. The analyst keeps a Buy rating on the shares.
10/18/17
BWSF
10/18/17
UPGRADE
Target $15
BWSF
Strong Buy
Verso upgraded to Strong Buy with $15 target at BWS Financial
BWS Financial analyst Hamed Khorsand upgraded Verso to Strong Buy from Buy with an unchanged price target of $15. The coated paper industry has essentially become a duopoly with Verso "having the larger piece of the pie," Khorsand tells investors in an intraday research note. The analyst says his updated estimates reflect only a portion of the announced price increases. He recommends buying shares of Verso ahead of the company's Q3 results and calls the company his top pick.
11/17/17
BWSF
11/17/17
NO CHANGE
Target $20
BWSF
Strong Buy
Verso price target raised to $20 from $15 at BWS Financial
BWS Financial analyst Hamed Khorsand raised his price target for Verso to $20 following the company's Q3 results. The continued reduction in on-hand inventory and competitors exiting the industry is expected to have a sizable impact on the coated paper market, Khorsand tells investors in a research note. He keeps a Strong Buy rating on Verso shares.
EXEL Exelixis
$29.65

-0.73 (-2.40%)

01/04/18
PIPR
01/04/18
NO CHANGE
Target $37
PIPR
Overweight
Piper ups Exelixis target to $37, names a top pick for 2018
Piper Jaffray analyst Edward Tenthoff names Exelixis a top pick for 2018 and raised his price target for the shares to $37 from $33. The analyst expects Cabometyx growth from driven label expansion and is positive into the Phase III Cotexo data in the first half of 2018.
10/16/17
PIPR
10/16/17
NO CHANGE
Target $33
PIPR
Overweight
Exelixis price target raised to $33 from $29 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Exelixis shares to $33 after the company said the Phase III Celestial trial of Cabometyx met the primary endpoint. The analyst is confident front-line approval next year will grow renal cell carcinoma product sales to $392M in 2018. He reiterates an Overweight rating on Exelixis.
10/16/17
RHCO
10/16/17
NO CHANGE
Target $35
RHCO
Buy
Cabo result better positions Exelixis as acquisition target, says SunTrust
SunTrust analyst Peter Lawson raised his price target on Exelixis (EXEL) to $35 from $33 and maintained his Buy rating, saying the latest CELESTIAL trial cabozantinib positions the treatment well against its main competitor - Bayer's (BAYRY) Regorafenib. Lawson adds that the trial result validates the expansion of cabozantinib beyond kidney cancer and better positions Exelixis as a potentially attractive M&A target.
10/17/17
NEED
10/17/17
NO CHANGE
Target $33
NEED
Buy
Exelixis price target raised to $33 from $30 at Needham
Needham analyst Chad Messer raised his price target on Exelixis (EXEL) to $33, noting the latest trial data for advanced renal cell carcinoma treatment, Cabozantinib, positions it for near and long term growth. Messer says the results may be sufficient to allay competitive concerns from the recently approved Bayer (BAYRY) Stivarga, as cabozantinib offers a potentially more attractive efficacy profile.
IPSEY Ipsen

09/19/17
SOCG
09/19/17
UPGRADE
SOCG
Buy
Ipsen upgraded to Buy from Hold at Societe Generale
Societe Generale analyst Delphine Le Louet upgraded Ipsen to Buy with a price target of EUR 126.
RNST Renasant
$43.86

0.15 (0.34%)

IBKR Interactive Brokers
$62.45

-0.65 (-1.03%)

04/19/17
04/19/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Ultragenyx (RARE) was downgraded to Neutral from Buy at H.C. Wainwright and to Neutral from Outperform at Wedbush. 2. Grainger (GWW) downgraded to Underperform on pricing risks at Credit Suisse with analyst Andrew Buscaglia telling investors he sees more uncertainty around its pricing strategy for its highest margin mid-sized customers and continued gross margin declines in 2018 that will weigh on shares. Buscaglia believes Grainger is the most susceptible to the Amazon (AMZN) threat as evidenced by its pricing actions to its more profitable smaller-medium sized customers and said its move online makes it more susceptible to competitive pricing. 3. Interactive Brokers (IBKR) downgraded to Market Perform at Keefe Bruyette with analyst Kyle Voigt citing the company's first quarter results. 4. Regions Financial (RF) downgraded to In Line from Outperform at Evercore ISI with analyst John Pancari citing limit upside to valuation given mounting earnings headwinds. 5. Sirius XM (SIRI) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Benjamin Swinburne telling investors the business is maturing and growth is slowing. Swinburne said Sirius is executing well, but the benefit from new car turnover has likely peaked and not longer adds material to the subscription base, and adds used car growth has also peaked. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/08/18
GSCO
01/08/18
NO CHANGE
GSCO
Goldman bullish on Brokers into 2018, upgrades Lazard and Stifel
Goldman Sachs analyst Conor Fitzgerald remains bullish on the Brokers and financial service companies heading into 2018. The analyst thinks large-cap mergers and acquisitions could accelerate and financial deals could return. To reflect these trends, Fitzgerald upgraded both Lazard (LAZ) and Stifel Financial (SF) to Buy from Neutral. The analyst prefers E-Trade (ETFC) and Charles Schwab (SCHW) over TD Ameritrade (AMTD) on the belief that commission price cuts are more likely than not in 2018. Further, Fitzgerald views Interactive Brokers' valuation as full and downgraded the shares to Sell from Neutral. Lastly, he sees a more balanced risk/reward for MarketAxess (MKTX) in this low volatility environment and downgraded the shares to Neutral from Buy.
01/08/18
GSCO
01/08/18
DOWNGRADE
Target $59
GSCO
Sell
Interactive Brokers downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Conor Fitzgerald downgraded Interactive Brokers to Sell while raising his price target for the shares to $59 from $43.
10/18/17
RHCO
10/18/17
NO CHANGE
Target $48
RHCO
Hold
Interactive Brokers price target raised to $48 from $40 at SunTrust
SunTrust analyst Douglas Mewhirter raised his price target on Interactive Brokers to $48 and kept his Hold rating following Q3 results that showed further strength in account growth and improved net interest income. Mewhirter says the company deserves a higher multiple than its peers in spite of lower trading volatility environment based on its highest asset growth in the industry. The analyst also adds that the 6% decline in Daily Average Revenue Trades - DART - per account was in part offset by 1% increase in revenue per DART.
CSX CSX
$58.13

-1.12 (-1.89%)

01/12/18
SCOT
01/12/18
DOWNGRADE
SCOT
Sector Perform
CSX downgraded to Sector Perform from Outperform at Scotiabank
01/09/18
RBCM
01/09/18
NO CHANGE
Target $67
RBCM
Outperform
RBC Capital raises price targets for Rails on Q4 volume growth and tax reform
RBC Capital analyst Walter Spracklin previews Q4 earnings for the Rail sector, saying volume grew about 4% while other performance metrics have been in line with prior years that saw similar growth rates. The analyst raises his price target on Canadian Pacific (CP) to CAD256 from CAD238 with an Outperform rating, calling it his "preferred name" based on solid volume, pricing trends, and relatively attractive valuation. Spracklin also ups CSX (CSX) price target to $67 from $59 with an Outperform rating, Norfolk Southern (NSC) price target to $137 from $123 with an Underperform rating, and Union Pacific (UNP) price target to $140 from $124 with a Sector Perform rating to reflect the positive impact of the U.S. corporate tax reform.
01/04/18
SBSH
01/04/18
NO CHANGE
Target $304
SBSH
Buy
Citi says all Transports win under U.S. tax bill
The Tax Cut and Jobs Act drives a "meaningful step up" in earnings as well as free cash flow for essentially all names in Transportation, Citi analyst Christian Wetherbee tells investors in a research note. He sees U.S. Rails as likely the biggest winners from tax reform. In most cases companies will use the cash "windfall" for buybacks, Wetherbee tells investors in a research note. He believes, however, that a compelling case can be made for U.S. Rails to increase dividends by 15%-20%. The free cash flow windfall could save UPS's (UPS) buyback program, which looked likely to decline in 2018 under the weight of accelerating capex, the analyst adds. Wetherbee upgraded C.H. Robinson Worldwide (CHRW) to Buy and downgraded Schneider National (SNCR) to Neutral. He also raised his price target for Buy-rated FedEx (FDX) to $304 from $280, Buy-rated CSX (CSX) to $64 from $58 and for Buy-rated UPS to $143 from $128.
01/12/18
CLVD
01/12/18
NO CHANGE
CLVD
CSX volume growth lagging peers, says Cleveland Research
Cleveland Research analyst Bryan Merolla's checks indicate CSX (CSX) volume growth continues to lag peers and expects Q4 results inline with lowered expectations.
ATEN A10 Networks
$7.31

-0.27 (-3.56%)

07/14/17
07/14/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Snap (SNAP) downgraded to Market Perform from Outperform at Cowen with analyst John Blackledge lowering his 2017 and longer-term advertising revenue estimates for Snap to reflect a more competitive environment within Digital advertising. He also believes contribution from the company's new advertising monetization products like Direct Response and Self Serve are not likely to be meaningful in the near term. 2. CyberArk (CYBR) was downgraded to Equal Weight from Overweight at Stephens, to Hold from Buy at Deutsche Bank, and to Neutral from Overweight at JPMorgan. 3. At Home Group (HOME) downgraded to Neutral from Buy at Goldman Sachs with analyst Matthew Fassler citing valuation with the shares up 82% since his upgrade to Buy on November 30, 2016. 4. A10 Networks (ATEN) downgraded to Sector Weight from Overweight at KeyBanc with analyst Alex Kurtz citing "substantially" lower projected growth rates following the company's weaker than expected preliminary second quarter results. 5. Himax (HIMX) downgraded to Underperform from Perform at Oppenheimer with analyst Andrew Uerkwitz saying lowered smartphone expectations in China for 2017 will weigh on the company's near-term orders. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/14/17
KEYB
07/14/17
DOWNGRADE
KEYB
Sector Weight
A10 Networks downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Alex Kurtz downgraded A10 Networks to Sector Weight citing "substantially" lower projected growth rates following the company's weaker than expected preliminary Q2 results. The analyst believes regaining demand momentum could take several quarters.
07/14/17
PIPR
07/14/17
DOWNGRADE
Target $136
PIPR
Neutral
F5 Networks downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Troy Jensen downgraded F5 Networks (FFIV) to Neutral and lowered his price target for the shares to $136 from $144. The product refresh cycle is not playing out as expected and product growth "could remain challenged," Jensen tells investors in a research note. His firm's Q2 channel survey highlighted a quarter-over-quarter downtick in demand for F5 with below plan responses outnumbering above plan responses, reversing a three quarter uptrend. Jensen says the negative preannouncement from A10 Networks (ATEN) only compounded his concerns. The analyst believes F5's previous growth assumptions and forward earnings are at risk.
HTGM HTG Molecular
$3.50

-0.14 (-3.85%)

01/05/18
ADAM
01/05/18
NO CHANGE
Target $5
ADAM
Buy
HTG Molecular price target raised to $5 from $4 at Canaccord
Canaccord analyst Mark Massaro raised his price target on HTG Molecular to $5 after the company announced preliminary fourth quarter results and provided initial full year 2018 revenue guidance.
HIVE Aerohive
$5.70

-0.19 (-3.23%)

05/04/17
WDLK
05/04/17
UPGRADE
Target $5
WDLK
Buy
Aerohive upgraded to Buy with $5 target at Wunderlich
Wunderlich analyst Matthew Robison upgraded Aerohive to Buy with a $5 price target following the company's Q1 results. The analyst views the stock as attractively valued given the company's progress.
05/04/17
WDLK
05/04/17
UPGRADE
WDLK
Buy
Aerohive upgraded to Buy from Hold at Wunderlich
10/17/17
10/17/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Groupon (GRPN) initiated with a Buy at Gabelli. 2. HP Enterprise (HPE) initiated with a Hold at Pivotal Research. 3. Celgene (CELG) initiated with an Outperform at Bernstein. 4. Aerohive (HIVE) initiated with a Buy at Craig-Hallum. 5. Sprouts Farmers Market (SFM) initiated with a Positive at Susquehanna. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/17/17
CHLM
10/17/17
INITIATION
Target $6
CHLM
Buy
Aerohive initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Christian Schwab started Aerohive with a Buy rating and $6 price target saying he really struggles to see how this distressed stock can get much worse from here, while seeing multiple paths to a much higher stock price.
OBLN Obalon Therapeutics
$7.93

0.03 (0.38%)

06/21/17
06/21/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Camping World (CWH) initiated with an Outperform at BMO Capital. 2. LendingTree (TREE) initiated with an Outperform at William Blair. 3. DST Systems (DST) initiated with a Buy at DA Davidson. 4. Obalon Therapeutics (OBLN) initiated with an Underperform at Northland. 5. First Defiance Financial (FDEF) initiated with a Hold at Sandler ONeill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/21/17
NORL
06/21/17
INITIATION
Target $6
NORL
Underperform
Obalon Therapeutics initiated with an Underperform at Northland
Northland analyst Suraj Kalia initiated Obalon with an Underperform and a $6 price target.
XON Intrexon
$13.77

-0.94 (-6.39%)

01/25/17
RODM
01/25/17
DOWNGRADE
Target $7
RODM
Neutral
GenVec downgraded to Neutral from Buy at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju downgraded GenVec (GNVC) to Neutral citing the takeover by Intrexon (XON). The analyst views the offer as "decent" and lowered his price target for GenVac shares to $7 from $15.
02/03/17
JMPS
02/03/17
NO CHANGE
Target $42
JMPS
Outperform
Dominion allows isobutanol option with Intrexon to expire, says JMP Securities
JMP Securities analyst Jason Butler said that Intrexon (XON) management confirmed in conversations with him yesterday after the markets closed that Dominion (D) allowed its option with Intrexon Energy Partners for isobutanol production facilities in North America to expire without opting in. While "somewhat disappointing," Butler said he remains confident that Intrexon and the IEP joint venture, which was formed with undisclosed investors that do not include Dominion, are making progress and Dominion's decision should not impact IEP's ability to continue advancing its efforts toward commercial production. He reiterates an Outperform rating and $42 price target on Intrexon shares.
11/10/17
STFL
11/10/17
NO CHANGE
Target $39
STFL
Buy
Intrexon price target lowered to $39 from $57 at Stifel
Stifel analyst Thomas Shrader lowered his price target on Intrexon to $39 from $57 citing "multiple issues," including longer than expected development times for its energy program and increased competitive pressure in gene therapy. However, he keeps a Buy rating on the shares, saying the company's call "seemed very positive," and noting management's increased focus on crop protection and away from mosquitos.
BOOT Boot Barn
$19.10

-0.15 (-0.78%)

08/04/17
BARD
08/04/17
UPGRADE
BARD
Outperform
Boot Barn upgraded to Outperform from Neutral at Baird
01/11/18
WELS
01/11/18
NO CHANGE
Target $20
WELS
Market Perform
Boot Barn price target raised to $20 from $11 at Wells Fargo
Wells Fargo analyst Tom Nikic raised his price target for Boot Barn to $20 from $11 to reflect tax reform. The analyst reiterates a Market Perform rating on the shares.
11/15/17
JPMS
11/15/17
UPGRADE
Target $17
JPMS
Overweight
Boot Barn upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Matthew Boss upgraded Boot Barn to Overweight and raised his price target for the shares to $17 from $9. After meeting with management, the analyst believes e-commerce will move from a headwind the past three quarters to a tailwind in the second half of 2017, "translating to a low-to-mid-single-digit same-store-sales story."
F Ford
$13.10

-0.13 (-0.98%)

12/28/17
MSCO
12/28/17
NO CHANGE
MSCO
January to be busy for Autos and Shared Mobility names, says Morgan Stanley
Morgan Stanley analyst Adam Jonas previewed the January calendar for the Autos and Shared Mobility sector, noting that the Vegas CES takes place in the second week and the Detroit Auto Show occurs in the third week of next month. Judging from last year's shows and press releases in recent weeks, he expects "the vast majority" of prepared presentations will focus on autonomous driving, electric propulsion and new business models as companies seek to encourage recognition and valuation of "Auto 2.0 efforts" in the multiples of their stocks, he tells investors. Automakers covered by the firm include Fiat Chrysler (FCAU), Tesla (TSLA), General Motors (GM), Ferrari (RACE) and Ford (F). Auto suppliers covered include Magna (MGA), Goodyear Tire (GT), Adient (ADNT), Delphi Technologies (DLPH), Visteon (VC), BorgWarner (BWA), Aptiv (APTV) and Tenneco (TEN).
10/31/17
MSCO
10/31/17
NO CHANGE
Target $10
MSCO
Underweight
Ford bull case view raised despite 'significant headwinds' at Morgan Stanley
Morgan Stanley analyst Adam Jonas raised his 2017 EPS estimate for Ford to near the midpoint of the company's guidance following its Q3 report and slightly increased his price target on the stock to $10 from $9. While he keeps an Underweight rating on Ford, stating that the headwinds it faces are significant, he also sees the "scope for an equally significant response" and raised his bull case to $25 from $18 given a sum-of-the-parts analysis under which he values Ford's truck business, including the F-series and others, at nearly $20 per share, Ford Europe, S. America and Asia Pacific at "slightly less than zero" and "Ford Future" at $3B, or 74c per Ford share.
10/30/17
GSCO
10/30/17
DOWNGRADE
GSCO
Sell
Goldman sees 28% downside in GM, downgrades shares to Sell
Goldman Sachs analyst David Tamberrino downgraded General Motors (GM) to Sell from Neutral saying his price target of $32 offers 28% potential downside. The analyst continues to believe the North America auto cycle has peaked and he remains cautious on the sector. He sees "outsized downside" to shares of GM and expects a negative earnings inflection in 2018. Ford's (F) recently refreshed F-Series leaves GM vulnerable to share loss in 2018, Tamberrino tells investors in a research note. The analyst views Ford shares as more fairly valued. He keeps a Neutral rating on the name while upping his target for the shares to $13 from $10.
12/21/17
OPCO
12/21/17
NO CHANGE
Target $9
OPCO
Outperform
TeleNav extension with Ford should remove overhang, says Oppenheimer
Craig-Hallum analyst Steven Dyer notes that TeleNav (TNAV) announced preliminary Q2 results and amended its current agreement with Ford (F), which he believes is net/net positive for the P&L and should be a catalyst for shares. The analyst thinks the extension with Ford removes a major overhang on shares as it provides visibility for the next three years. Dyer reiterates an Outperform rating on TeleNav's shares, while lowering his price target on the stock to $9 from $12.

TODAY'S FREE FLY STORIES

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

16:26
02/24/18
02/24
16:26
02/24/18
16:26
Hot Stocks
Buffett believes Berkshire can handle $400B mega-catastrophe »

In his annual letter to…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

16:19
02/24/18
02/24
16:19
02/24/18
16:19
Periodicals
Buffet says laments inability to find targets for Berkshire to buy, Reuters says »

Warren Buffett lamented…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

16:16
02/24/18
02/24
16:16
02/24/18
16:16
Periodicals
Berkshire Hathaway reports record profit fueled by tax reform, Reuters says »

Berkshire Hathaway…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$32.66

0.55 (1.71%)

16:12
02/24/18
02/24
16:12
02/24/18
16:12
Periodicals
Twitter's SoundCloud investment officially wiped out, Recode reports »

Twitter has written off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

AAPL

Apple

$175.50

3 (1.74%)

16:08
02/24/18
02/24
16:08
02/24/18
16:08
Periodicals
Apple to store sensitive encryption keys in China, WSJ reports »

Apple will start to store…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$40.98

0.09 (0.22%)

16:00
02/24/18
02/24
16:00
02/24/18
16:00
Periodicals
Volkswagen's U.S. unit settles emissions suit, Reuters reports »

Volkswagen's unit in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DAL

Delta Air Lines

$53.46

0.91 (1.73%)

, UAL

United Continental

$67.57

0.87 (1.30%)

15:56
02/24/18
02/24
15:56
02/24/18
15:56
Periodicals
Delta, United Airlines cut ties with NRA, Reuters reports »

Delta Air Lines (DAL) and…

DAL

Delta Air Lines

$53.46

0.91 (1.73%)

UAL

United Continental

$67.57

0.87 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 30

    May

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

15:53
02/24/18
02/24
15:53
02/24/18
15:53
Earnings
Berkshire Hathaway reports Q4 operating EPS $3,338, consensus $2,622.23 »

Reports FY17 operating…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$94.70

0.33 (0.35%)

, T

AT&T

$36.72

0.25 (0.69%)

15:44
02/24/18
02/24
15:44
02/24/18
15:44
Periodicals
May be time to consider Time Warner, Barron's says »

Time Warner (TWX) shares…

TWX

Time Warner

$94.70

0.33 (0.35%)

T

AT&T

$36.72

0.25 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 05

    Mar

  • 06

    Mar

  • 23

    Apr

JKHY

Jack Henry

$121.95

1.79 (1.49%)

12:59
02/24/18
02/24
12:59
02/24/18
12:59
Conference/Events
Jack Henry management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

PFBC

Preferred Bank

$64.05

0.86 (1.36%)

12:52
02/24/18
02/24
12:52
02/24/18
12:52
Conference/Events
Preferred Bank management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 13

    Mar

  • 24

    Sep

R

Ryder

$74.54

0.19 (0.26%)

12:47
02/24/18
02/24
12:47
02/24/18
12:47
Conference/Events
Ryder management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

ASPU

Aspen Group

$8.85

1.48 (20.08%)

12:29
02/24/18
02/24
12:29
02/24/18
12:29
Conference/Events
Aspen Group to hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

TWTR

Twitter

$32.66

0.55 (1.71%)

, AOBC

American Outdoor Brands

$10.00

-0.12 (-1.19%)

10:47
02/24/18
02/24
10:47
02/24/18
10:47
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

TWTR

Twitter

$32.66

0.55 (1.71%)

AOBC

American Outdoor Brands

$10.00

-0.12 (-1.19%)

RGR

Sturm, Ruger

$49.90

0.9 (1.84%)

X

U.S. Steel

$43.52

0.54 (1.26%)

STLD

Steel Dynamics

$47.47

-0.53 (-1.10%)

NUE

Nucor

$66.94

-0.01 (-0.01%)

AKS

AK Steel

$5.50

-0.12 (-2.14%)

AET

Aetna

$175.55

0.49 (0.28%)

ANTM

Anthem

$235.24

1.56 (0.67%)

CNC

Centene

$100.45

0.96 (0.96%)

CI

Cigna

$194.79

2.89 (1.51%)

HNT

Health Net

HUM

Humana

$271.19

3.38 (1.26%)

MOH

Molina Healthcare

$72.94

1.38 (1.93%)

UNH

UnitedHealth

$230.16

3.07 (1.35%)

WCG

WellCare

$192.05

0.03 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 01

    Mar

  • 07

    Mar

  • 13

    Mar

  • 16

    Apr

  • 30

    May

DBX

Dropbox

, SNAP

Snap

$17.45

-0.06 (-0.34%)

09:49
02/24/18
02/24
09:49
02/24/18
09:49
Periodicals
Dropbox IPO bodes well, Barron's says »

In a follow-up article…

DBX

Dropbox

SNAP

Snap

$17.45

-0.06 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

IPG

Interpublic Group

$24.24

0.3 (1.25%)

, OMC

Omnicom

$77.31

0.52 (0.68%)

09:42
02/24/18
02/24
09:42
02/24/18
09:42
Periodicals
Advertising companies cheaper than usual, Barron's says »

After a tumble last year,…

IPG

Interpublic Group

$24.24

0.3 (1.25%)

OMC

Omnicom

$77.31

0.52 (0.68%)

PUBGY

Publicis

$18.82

0.09 (0.48%)

WPP

WPP

$95.30

0.93 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 05

    Mar

MSFT

Microsoft

$94.06

2.33 (2.54%)

, INTC

Intel

$47.73

1.93 (4.21%)

09:36
02/24/18
02/24
09:36
02/24/18
09:36
Periodicals
Quantum computing soon to be reality, Barron's says »

Microsoft (MSFT) predicts…

MSFT

Microsoft

$94.06

2.33 (2.54%)

INTC

Intel

$47.73

1.93 (4.21%)

NVDA

Nvidia

$245.93

3.78 (1.56%)

MU

Micron

$46.53

2.28 (5.15%)

GOOG

Alphabet

$1,126.79

20.16 (1.82%)

GOOGL

Alphabet Class A

$1,128.09

18.19 (1.64%)

AMZN

Amazon.com

$1,500.00

14.66 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 28

    Feb

  • 07

    Mar

  • 07

    Mar

  • 13

    Mar

  • 14

    Mar

  • 18

    Mar

  • 22

    Mar

  • 22

    Mar

  • 23

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 30

    May

AMZN

Amazon.com

$1,500.00

14.66 (0.99%)

09:26
02/24/18
02/24
09:26
02/24/18
09:26
Periodicals
Many downsides when Amazon's HQ2 comes to town, Barron's says »

As Amazon decides on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 18

    Mar

BHGE

Baker Hughes

$28.03

-0.01 (-0.04%)

04:55
02/24/18
02/24
04:55
02/24/18
04:55
Conference/Events
Baker Hughes management to meet with UBS »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

GE

General Electric

$14.49

-0.01 (-0.07%)

18:49
02/23/18
02/23
18:49
02/23/18
18:49
Periodicals
General Electric could face DOJ action over subprime mortgages, Reuters says »

General Electric may face…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$20.15

0.34 (1.72%)

18:30
02/23/18
02/23
18:30
02/23/18
18:30
Syndicate
Bright Scholar files to sell 10M American Depositary Shares »

Each ADS represents one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

, CMD

Cantel Medical

$115.34

2.45 (2.17%)

18:03
02/23/18
02/23
18:03
02/23/18
18:03
Periodicals
J&J sterilization unit draws bids from Cantel Medical, Medtronic, Bloomberg says »

Cantel Medical (CMD) and…

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

CMD

Cantel Medical

$115.34

2.45 (2.17%)

MDT

Medtronic

$80.39

-0.02 (-0.02%)

KKR

KKR

$21.96

0.18 (0.83%)

CG

Carlyle Group

$23.15

-0.1 (-0.43%)

MMM

3M

$237.02

1.02 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 08

    Mar

  • 14

    Mar

  • 23

    Mar

  • 23

    Apr

  • 30

    May

AET

Aetna

$175.55

0.49 (0.28%)

, CVS

CVS Health

$68.16

0.16 (0.24%)

18:00
02/23/18
02/23
18:00
02/23/18
18:00
Hot Stocks
Aetna: CVS deal part of long-term solution toward value-based system »

According to prepared…

AET

Aetna

$175.55

0.49 (0.28%)

CVS

CVS Health

$68.16

0.16 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

  • 30

    May

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:56
02/23/18
02/23
17:56
02/23/18
17:56
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:55
02/23/18
02/23
17:55
02/23/18
17:55
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.